Worldwide genetics of bile duct (cholangiocarcinoma)
Official title: International Consortium for the Genetics of Biliary Tract Cancers Cholangiocarcinoma Genome Wide Association Study
Funded at Mayo Clinic Rochester · NIH-11399765 · Data updated 2026-11-12
Researchers are looking for genetic patterns that raise the risk of bile duct cancer in people from diverse regions worldwide.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | April 10, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $620,190 |
| NIH project number | 5U01CA275065-04 |
| Project ID | NIH-11399765 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants include people diagnosed with cholangiocarcinoma, people with high-risk conditions such as PSC, and matched control volunteers willing to provide a blood or saliva sample and medical information at participating sites.
✕Less likely to help
People seeking immediate treatment benefit for advanced disease or those unwilling to provide samples and health information are unlikely to gain direct short-term benefit from this genetics work.
What this research studies
This project gathers DNA and clinical information from people with cholangiocarcinoma and matched controls across multiple countries and ancestry groups. Scientists will use genome-wide scans to find genetic variants more common in people who develop bile duct cancer, including those with known conditions like primary sclerosing cholangitis. The work combines samples and data from international centers to increase the number of patients studied and improve the chance of finding meaningful genetic signals. Results will be compared across ancestry groups to find shared and population-specific risk factors.
Why it matters
Potential benefit: If successful, this could help identify people at higher genetic risk for bile duct cancer and guide earlier detection, prevention, and new treatment strategies.
How similar studies have gone: Genome-wide studies have uncovered risk genes for many cancers, but large GWAS specifically focused on cholangiocarcinoma have been limited, making this effort relatively novel for this cancer type.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Roberts, Lewis R — Mayo Clinic Rochester
- Study coordinator: Roberts, Lewis R
Related research
Other NIH-funded projects on the same topics.
-
A new mouse model to study intrahepatic cholangiocarcinoma and its immunotherapy
A new mouse model helps researchers understand intrahepatic cholangiocarcinoma and test immune-based treatments to improve outcomes.
-
Radiation plus a patient’s own immune cells to boost cholangiocarcinoma treatment
This project tests a therapy that combines precise radiation and the patient’s own dendritic cells with immune drugs to help fight intrahepatic cholangiocarcinoma in people who cannot have surgery.
-
MKK4 and Liver Regeneration after Major Liver Surgery
A study at Mayo Clinic will test a new drug, HRX215, to help people regrow liver tissue after major liver surgery for cancer.
-
New mouse model to improve immune therapy for intrahepatic bile duct (cholangiocarcinoma) cancer
This project builds a new mouse model to help make immune-based treatments work better for people with intrahepatic cholangiocarcinoma, a type of bile duct liver cancer.
-
Mutant IDH in bile duct cancer and its impact on immune response
A patient-facing look at how mutations in IDH1 drive bile duct cancer and how targeting this mutation could help immune cells fight the tumor.
-
Understanding a tumor-promoting immune pathway in bile duct cancer
A new NIH grant aims to test how a specific immune protein, B7-H4, helps cholangiocarcinoma grow and how blocking it might slow the cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.